KVUE Stock Recent News

An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company's latest legal issue involving talc products.

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Alex Fitch, Harris Associates director of U.S. Research, joins 'Money Movers' to discuss Fitch's investment thesis towards Delta Air Lines, whether investors are not supposed to buy cyclical stocks at peak earnings, and more.

Kenvue (NYSE: KVUE ) has announced plans to lay off over 100 employees at one of its leading brands. Specifically, the prominent skincare, cosmetics and health company will be implementing job cuts at Neutrogena, a well-known name in the health and beauty space.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue, the world's largest pure-play consumer health company by revenue, will announce its 2024 Q1 results before market open on May 7, 2024.

ALERT: Today Could Be Your Best Shot At Early Retirement (Sponsored) If you want to retire before 65, pay attention.

At first glance, a concerted focus on stable blue-chip stocks might seem excessively cautious. After all, the market is booming, companies are hiring and people are spending.

Kenvue, a spin-off from Johnson & Johnson, has solid financials and a strong portfolio of iconic consumer products. The company's dividend is safe with a conservative payout ratio, and they initiated a share repurchase program during Q3. Because of this, I've initiated the stock as a speculative buy currently. Kenvue has a strong balance sheet and a lower valuation compared to other consumer staple stocks, making it an attractive investment opportunity.

Band-Aid maker Kenvue Inc (NYSE:KVUE) saw its shares hit on Thursday morning after laying out guidance below Wall Street expectations. Kenvue said adjusted profit would sit between US$1.10 to US$1.20 per share for the year ahead in Thursday's fourth quarter results, lower than analysts' estimates of US$1.26.

Kenvue forecast full-year profit below analysts' expectations after missing quarterly sales estimates on Thursday, as the Tylenol maker faces sluggish demand in China and slowing growth for skin and beauty products in the U.S. The company, spun off from Johnson & Johnson in August, missed Street estimates for fourth-quarter sales in both its self-care, as well as skin health and beauty segments.